156 related articles for article (PubMed ID: 33910332)
21. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X
Yao W; Bai L; Wang S; Zhai Y; Sun SY
Neoplasia; 2022 Jul; 29():100798. PubMed ID: 35462114
[TBL] [Abstract][Full Text] [Related]
22. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.
Day BW; Stringer BW; Spanevello MD; Charmsaz S; Jamieson PR; Ensbey KS; Carter JC; Cox JM; Ellis VJ; Brown CL; Walker DG; Inglis PL; Allan S; Reynolds BA; Lickliter JD; Boyd AW
Neuro Oncol; 2011 Nov; 13(11):1202-12. PubMed ID: 21846680
[TBL] [Abstract][Full Text] [Related]
23. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
Touzeau C; Ryan J; Guerriero J; Moreau P; Chonghaile TN; Le Gouill S; Richardson P; Anderson K; Amiot M; Letai A
Leukemia; 2016 Mar; 30(3):761-4. PubMed ID: 26174630
[No Abstract] [Full Text] [Related]
24. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
25. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
29. Mapping the BH3 Binding Interface of Bcl-xL, Bcl-2, and Mcl-1 Using Split-Luciferase Reassembly.
Campbell ST; Carlson KJ; Buchholz CJ; Helmers MR; Ghosh I
Biochemistry; 2015 Apr; 54(16):2632-43. PubMed ID: 25844633
[TBL] [Abstract][Full Text] [Related]
30. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
Zhou XJ; Zhou YH; Chen XH; Qian WB
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369
[TBL] [Abstract][Full Text] [Related]
31. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
33. MCL-1 and BCL-XL: blood brothers.
Erlacher M; Labi V
Blood; 2021 Apr; 137(14):1850-1851. PubMed ID: 33830190
[No Abstract] [Full Text] [Related]
34. Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming.
Conage-Pough JE; Boise LH
FEBS J; 2018 Jul; 285(14):2626-2640. PubMed ID: 29775995
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications.
Aksoy O; Lind J; Sunder-Plaßmann V; Vallet S; Podar K
Cytokine; 2023 Jan; 161():156062. PubMed ID: 36332463
[TBL] [Abstract][Full Text] [Related]
36. NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and "osmotic reprogramming" in colorectal cancer.
Knoll G; Riffelsberger P; Raats D; Kranenburg O; Ehrenschwender M
Cell Death Dis; 2020 Apr; 11(4):257. PubMed ID: 32312973
[TBL] [Abstract][Full Text] [Related]
37. Mcl-1 downregulation by pro-inflammatory cytokines and palmitate is an early event contributing to β-cell apoptosis.
Allagnat F; Cunha D; Moore F; Vanderwinden JM; Eizirik DL; Cardozo AK
Cell Death Differ; 2011 Feb; 18(2):328-37. PubMed ID: 20798690
[TBL] [Abstract][Full Text] [Related]
38. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL.
Dutta S; Gullá S; Chen TS; Fire E; Grant RA; Keating AE
J Mol Biol; 2010 May; 398(5):747-62. PubMed ID: 20363230
[TBL] [Abstract][Full Text] [Related]
39. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
[No Abstract] [Full Text] [Related]
40. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
